Clinical Phage Production - Design/Build/Qualify
Challenge from the Client
A start-up biotech company was looking to generate phase 1 and phase 2 clinical material for a phage-based therapy on an aggressive timeline and tight budget.
Our Approach & Solution
By bringing isolation/closure of the entirety of the process (cell culture, infection, purification, formulation, filling) a small existing lab space was able to be minimally renovated.
The Results
This approach allowed the client to go from business need identification to qualified space for drug substance and aseptic drug product in four months.
Related Molecules
Gene Therapy Facility
Read MoreOur client needed an efficient design for their gene biologics plant within an existing building with limited space for air handlers and mechanical equipment.
Large-Scale Bulk Manufacturing Facility
Read MoreIPS built a new greenfield facility in Ireland for bulk biologics manufacturing with single-use technology under an extremely aggressive timeline.
Single-Use Mammalian Cell Culture Facility - Vial to Vial
Read MoreOur challenge was to design a biologics manufacturing launch facility within an existing shell & office building.
Fast-Track Project Delivery Model
Read MoreA vaccine manufacturer and distributor needed IPS’ expertise to meet an aggressive timeline for expansion of their production facility.
Detailed Process Piping
Read MoreSupporting a client’s dynamic business requirements to produce a near-fabrication-level model to reduce schedule time.
Water For Injection (WFI) Generation System Design for a Global CMO Biotechnology Facility for the Manufacture of mAb/Recombinant Protein
Read MoreBiotech CMO client needed an n+1 redundant system to handle increased WFI demand, while reducing operating costs.
Commercial Manufacturing of Autologous Muscle Derived Cell (AMDC) products
Read MoreApplying industry-leading knowledge and expertise to support CGMP-compliant manufacturing process scale-up.
Largest Single-use Based mAb Facility in the World
Read MoreOur CMO client wanted to do something radically different by creating a multiproduct, multiscale mAb facility that could flex upstream capacity in 2000L intervals.
Antibody Drug Conjugation Commercial Manufacturing
Read MoreApplied first class design tools and industry specific experiences to develop a greenfield site for commercial ADC manufacturing.
Mammalian Cell Culture to COVID-19 Vaccine Adjuvant in 3 weeks
Read MoreSoon after the COVID-19 outbreak, our client's direction shifted quickly from a mammalian cell culture facility to a COVID-19 vaccine adjuvant production facility.
Delivering a New Building with Two Project Teams
Read MoreProvided a client and building tenant with construction management services for the interior fit-out of a new 50,000sf pharmaceutical testing facility while a separate vendor constructs the core & shell for the landlord.
Annex 1 - The Brave New World of Aseptic Regulatory Compliance
Read MoreAfter six years in review, the final emergence of Annex 1 in August 2022 has either been a consolidation of accepted practice and wisdom, or a rude awakening for many!
